Human papillomavirus immunisation of adolescent girls and anticipated reporting of immune-mediated adverse events

Vaccine

Volumn 27, Issue 22, 2009, Pages 2954-2958

  Callréus, Torbjörn ^a   Svanström, Henrik ^a   Nielsen, Nete Munk ^a   Poulsen, Sigrid ^b   Valentiner Branth, Palle ^a   Hviid, Anders ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b Sundhedsstyrelsen   (Denmark)

Author keywords

Adverse events; Human papillomavirus; Vaccines

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ALLERGIC CONJUNCTIVITIS; ALLERGIC DISEASE; ALLERGIC RHINITIS; ANAPHYLACTIC SHOCK; ANGIONEUROTIC EDEMA; ARTICLE; ASTHMA; ASTHMATIC STATE; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; DENMARK; DRUG SAFETY; FEMALE; HUMAN; IMMUNE MEDIATED DISORDER; IMMUNE SYSTEM; IMMUNIZATION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRIORITY JOURNAL; SKIN ALLERGY; STATISTICAL ANALYSIS; URTICARIA; WART VIRUS;

ADOLESCENT; AUTOIMMUNE DISEASES; CHILD; DENMARK; FEMALE; HUMANS; HYPERSENSITIVITY; INCIDENCE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 65049086225     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.02.106     Document Type: Article

References (17)

1. Guideline on Risk Management Systems For Medicinal Products For Human Use, 14 November 2005. http://www.emea.europa.eu/pdfs/human/euleg/9626805en.pdf. Accessed 13 January 2009.
2. Guidance for Industry: Development and Use of Risk Minimization Action Plans, March 2005. http://www.fda.gov/cder/guidance/6358fnl.htm. Accessed 13 January 2009.
3. Waller P. Risk management planning: time to deliver. Pharmacoepidemiol Drug Saf 15 12 (2006) 850-851
4. ICH Harmonised Tripartite Guideline: Pharmacovigilance planning (E2E), 18 November 2004. http://www.ich.org/LOB/media/MEDIA1195.pdf. Accessed 13 January 2009.
5. Bonhoeffer J., and Heininger U. Adverse events following immunization: perception and evidence. Curr Opin Infect Dis 20 June (3) (2007) 237-246
6. Global Advisory Committee on Vaccine Safety, 12-13 June 2007. Wkly Epidemiol Rec 2007;82(July 20 (28-29)):252-9.
7. Halsey N.A. The human papillomavirus vaccine and risk of anaphylaxis. CMAJ 179 September 9 (6) (2008) 509-510
8. Kalaboka S., and Annesi-Maesano I. The complex link between immunization against childhood diseases and allergy. Expert Rev Vaccines 6 August (4) (2007) 635-643
9. Wraith D.C., Goldman M., and Lambert P.H. Vaccination and autoimmune disease: what is the evidence?. Lancet 362 November 15 (9396) (2003) 1659-1666
10. Wagner-Weiner L. Pediatric rheumatology for the adult rheumatologist. J Clin Rheumatol 14 April (2) (2008) 109-119
11. Siegrist C.A. Autoimmune diseases after adolescent or adult immunization: what should we expect?. CMAJ 177 November 20 (11) (2007) 1352-1354
12. Malig C. The Civil Registration System in Denmark. Bethesda, Maryland: International Institute for Vital Registration and Statistics; 1996. Report No.: IIVRS Technical Paper, No. 66.
13. Andersen T.F., Madsen M., Jorgensen J., Mellemkjoer L., and Olsen J.H. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 46 June (3) (1999) 263-268
14. Haynes B.F., and Fauci A.S. Introduction to the immune system. In: Fauci A.S., Braunwald E., and Isselbacher K.J. (Eds). Harrison's principles of internal medicine. 14 ed. (1998), McGraw-Hill. Health Profession Division, New York 1753-1776
15. Senior K. Global aspirations for HPV vaccination. Lancet Infect Dis 8 March (3) (2008) 150
16. Siegrist C.A., Lewis E.M., Eskola J., Evans S.J., and Black S.B. Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions. Pediatr Infect Dis J 26 November (11) (2007) 979-984
17. Coombes R. Life saving treatment or giant experiment?. BMJ 334 April 7 (7596) (2007) 721-723